文献速递临床试验与 GCP真实世界研究与卫生经济

HEALTH试验:腹腔镜宫颈上子宫切除术对比二代子宫内膜消融术治疗月经过多的随机对照试验方案

HEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2018-01-24

HEALTH试验旨在比较腹腔镜宫颈上子宫切除术(LASH)与二代子宫内膜消融术(EA)治疗月经过多(HMB)的临床与成本效果。研究对象为<50岁、药物治疗失败且适合EA的女性,计划从英国约30个二级医疗中心招募,主要结局通过术后疼痛日记及6周、6个月和随机化后15个月的问卷评估。

要点

  • 比较LASH与二代EA治疗HMB的临床与成本效果。
  • 纳入<50岁、药物治疗失败且适合EA的女性。
  • 计划从英国约30个开展两种手术的二级医疗中心招募。

核心结论

  • HEALTH试验旨在回答LASH是否在临床与成本效果方面优于二代EA治疗HMB。

研究设计与样本

  • 随机对照试验方案,计划从英国约30个开展LASH和EA的二级医疗中心招募<50岁、药物治疗失败且适合EA的HMB女性。
  • 所有同意者完成术后第1至14天疼痛日记,术后6周、6个月及随机化后15个月邮寄问卷,并在6周、6个月和15个月完成医疗资源利用问题。

关键数值与推荐

  • 研究对象为<50岁、HMB、药物治疗失败且适合EA的女性。
  • 主要比较LASH与二代EA的临床与成本效果。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy, i.e. surgical removal of the uterus. While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other pelvic structures. The procedure can be simplified and complications minimised by undertaking a 'supracervical' hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which can be performed as a day-case procedure and is relatively easy for the surgeon to learn. HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question 'Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?' METHODS/DESIGN: Women aged < 50 years, with HMB, in whom medical treatment has failed and who are eligible for EA will be considered for trial entry. We aim to recruit women from approximately 30 active secondary care centres in the UK NHS who carry out both surgical procedures. All women who consent will complete a diary of pain symptoms from day 1 to day 14 after surgery, postal questionnaires at six weeks and six months after surgery and 15 months post randomisation. Healthcare utilisation questions will also be completed at the six-week, six-month and 15-month time-points. DISCUSSION: Measuring the comparative effectiveness of LASH vs EA will provide the robust evidence required to determine whether the new technique should be adopted widely in the NHS. TRIAL REGISTRATION: International Standard Randomised Controlled Trials, ISRCTN49013893 . Registered on 28 January 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cooper K, McCormack K, Breeman S, et al. HEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial. Trials. 2018. PMID: 29368658. doi:10.1186/s13063-017-2374-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。